search
Back to results

Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy (DUART)

Primary Purpose

Non-small Cell Lung Cancer

Status
Active
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Durvalumab
Sponsored by
AstraZeneca
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Non-small Cell Lung Cancer focused on measuring Radiation therapy, Phase II, Palliative Radiotherapy

Eligibility Criteria

18 Years - 130 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Capable of giving signed informed consent.
  2. Age ≥ 18 years at study entry.
  3. Histologically or cytologically documented NSCLC with locally-advanced, unresectable Stage III disease.
  4. Deemed ineligible for chemotherapy per Investigator assessment.
  5. Receipt of radiation therapy that was completed within 42 days prior to first study drug administration.
  6. Must have received a total dose of radiation of 40 to 66 Gy (standard or hypofractionated BED).
  7. Must not have progressed following radiation therapy, as per Investigator assessed RECIST 1.1 criteria: a) Patients with measurable disease and/or nonmeasurable and/or no evidence of disease assessed at baseline by computed tomography /magnetic resonance imaging will be eligible for this study. b) Prior irradiated lesions may be considered measurable and selected as target lesions (TLs) providing they fulfill the other criteria for measurability.
  8. World Health Organization/ECOG performance status of ≤2.
  9. No prior exposure to immune-mediated therapy including, but not limited to, anti-CTLA-4, anti-PD-1, anti-PD-L1, and antiprogrammed cell death ligand 2 (anti-PD-L2) antibodies, excluding therapeutic anticancer vaccines.
  10. Patients must have adequate organ and marrow function as defined below:

    • Hemoglobin ≥ 9.0 g/dL
    • Absolute neutrophil count ≥ 1.0 × 109 /L
    • Platelet count ≥ 75 × 109/L
    • Serum bilirubin ≤ 1.5 × the upper limit of normal (ULN). This will not apply to patients with confirmed Gilbert's syndrome.
    • Alanine aminotransferase and aspartate aminotransferase ≤ 2.5 × ULN
    • Measured creatinine clearance > 30 mL/min or calculated CL > 30 mL/min as determined by Cockcroft-Gault
  11. Life expectancy of greater than 12 weeks.
  12. Body weight greater than 30 kg at study entry and at first study drug administration

Exclusion Criteria:

  1. Patients with locally-advanced NSCLC whose disease has progressed following radiation therapy.
  2. Mixed small cell lung cancer and NSCLC histology.
  3. History of allogeneic organ transplantation.
  4. Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative, systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome).
  5. Uncontrolled intercurrent illness (e.g., ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris)
  6. History of another primary malignancy except for (a) malignancy treated with curative intent and with no known active disease ≥ 5 years before the first study drug administration, (b) adequately treated nonmelanoma skin cancer or lentigo maligna without evidence of disease, and c) treated carcinoma in situ without evidence of disease.
  7. History of leptomeningeal carcinomatosis
  8. History of active primary immunodeficiency
  9. Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus
  10. Any unresolved toxicity NCI CTCAE Grade ≥ 2 from previous anticancer therapy with the exception of alopecia, vitiligo, lymphopenia, and the laboratory values defined in the inclusion criteria
  11. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
  12. Receipt of live attenuated vaccine within 30 days prior to the first dose of durvalumab
  13. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of durvalumab.
  14. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab.
  15. Participation in another clinical study with an IP administered in the last 4 weeks.
  16. Concurrent enrollment in another clinical study, unless it is an observational (noninterventional) clinical study or during the follow-up period of an interventional study
  17. Prior randomization or treatment in a previous durvalumab clinical study regardless of treatment arm assignment
  18. Patients who refuse chemotherapy by their own decision.
  19. Involvement in the planning and/or conduct of the study
  20. Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control.
  21. Judgment by the Investigator that the patient should not participate in the study
  22. Genetics research study (optional):

Exclusion criteria for participation in the optional genetics research component of the study include: a) Previous allogeneic bone marrow transplant b)Nonleukocyte-depleted whole blood transfusion within 120 days of genetic sample collection.

Sites / Locations

  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Cohort A

Cohort B

Arm Description

Patients received standard radiotherapy [60 gray (Gy) ± 10% or hypofractionated BED] prior to study entry.

Patients received palliative radiotherapy [40 to < 54 Gy or hypofractionated BED] prior to study entry.

Outcomes

Primary Outcome Measures

Number of participants with Grade 3 and Grade 4 possibly-related adverse events (PRAEs)
To assess the safety and tolerability profile of durvalumab as defined by Grade 3 and Grade 4 PRAEs

Secondary Outcome Measures

Median Progression-free survival (PFS)
To assess the efficacy of durvalumab treatment . PFS is defined as the time from the first date of treatment until the date of objective disease progression or death regardless of whether the patient withdraws from investigational product (IP) or receives another anticancer therapy prior to progression
PFS at 6 months (PFS6)
To assess the efficacy of durvalumab treatment . PFS is defined as the time from the first date of treatment until the date of objective disease progression or death regardless of whether the patient withdraws from IP or receives another anticancer therapy prior to progression
PFS at 12 months (PFS12)
To assess the efficacy of durvalumab treatment. PFS is defined as the time from the first date of treatment until the date of objective disease progression or death regardless of whether the patient withdraws from IP or receives another anticancer therapy prior to progression
Median overall survival (OS)
To assess the efficacy of durvalumab treatment. OS is defined as the time from the first date of treatment until death due to any cause
OS at 12 months (OS12)
To assess the efficacy of durvalumab treatment. OS is defined as the time from the first date of treatment until death due to any cause
Objective response rate (ORR)
To assess the efficacy of durvalumab treatment in terms of ORR based on Investigator assessments per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Duration of response (DoR)
To assess the efficacy of durvalumab treatment in terms of DoR. DoR is defined as the time from the date of first documented response per RECIST1.1 until the first date of documented progression per RECIST1.1 or death in the absence of disease progression
Number of participants with lung cancer mortality
To assess the efficacy of durvalumab treatment in terms of lung cancer mortality
Number of participants with adverse events, serious adverse events, adverse event of special interests, and immune-mediated adverse event
To assess the safety and tolerability profile of durvalumab treatment
Number of participants with abnormal physical examinations
To assess the safety and tolerability profile of durvalumab treatment
Number of participants with abnormal blood pressure
To assess the safety and tolerability profile of durvalumab treatment
Number of participants with abnormal pulse
To assess the safety and tolerability profile of durvalumab treatment
Number of participants with abnormal electrocardiograms
To assess the safety and tolerability profile of durvalumab treatment
Number of participants with abnormal clinical chemistry
To assess the safety and tolerability profile of durvalumab treatment
Number of participants with abnormal hematology
To assess the safety and tolerability profile of durvalumab treatment
Number of participants with abnormal urinalysis
To assess the safety and tolerability profile of durvalumab treatment

Full Information

First Posted
January 29, 2020
Last Updated
August 22, 2023
Sponsor
AstraZeneca
search

1. Study Identification

Unique Protocol Identification Number
NCT04249362
Brief Title
Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy
Acronym
DUART
Official Title
A Phase II, Open-label, Multicenter, International Study of Durvalumab Following Radiation Therapy in Patients With Stage III, Unresectable Non-Small Cell Lung Cancer Who Are Ineligible for Chemotherapy
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
November 26, 2020 (Actual)
Primary Completion Date
March 30, 2023 (Actual)
Study Completion Date
January 6, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AstraZeneca

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes

5. Study Description

Brief Summary
This is a Phase II open-label, single-arm, multicenter, international study to evaluate the clinical activity of durvalumab in patients with Stage III unresectable NSCLC who are deemed to be ineligible for chemotherapy per Investigator assessment. Patients will be enrolled into 2 cohorts according to radiotherapy pretreatment dose (Cohort A: standard radiation therapy [60 gray (Gy) ± 10% or hypofractionated bioequivalent dose (BED)]; Cohort B: palliative radiation therapy [40 to < 54 Gy or hypofractionated BED])
Detailed Description
This is a Phase II open-label, single-arm, multicenter, international study to evaluate the clinical activity of durvalumab in patients with Stage III unresectable NSCLC who have an Eastern Cooperative Oncology Group (ECOG) PS of 0 to 2 and who were treated with radiotherapy but are ineligible for chemotherapy. Patients will be enrolled into 2 cohorts according to the dose of radiotherapy received prior to study entry (Cohort A: Standard Radiotherapy [60 Gy ± 10% or hypofractionated BED]; Cohort B: Palliative Radiotherapy [40 to < 54 Gy or hypofractionated BED]). Patients must not have progressed following radiation therapy, and radiation therapy must be completed within 6 weeks (42 days) prior to first study drug administration. The last dose of radiation therapy is defined as the day of the last radiation treatment session. All patients will receive 1500 mg durvalumab via IV infusion every 4 weeks (q4w) for up to a maximum of 12 months (up to 13 doses/cycles)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-small Cell Lung Cancer
Keywords
Radiation therapy, Phase II, Palliative Radiotherapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
102 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cohort A
Arm Type
Experimental
Arm Description
Patients received standard radiotherapy [60 gray (Gy) ± 10% or hypofractionated BED] prior to study entry.
Arm Title
Cohort B
Arm Type
Experimental
Arm Description
Patients received palliative radiotherapy [40 to < 54 Gy or hypofractionated BED] prior to study entry.
Intervention Type
Drug
Intervention Name(s)
Durvalumab
Other Intervention Name(s)
MEDI4736
Intervention Description
All patients will receive 1500 mg durvalumab via IV infusion q4w for up to a maximum of 12 months.
Primary Outcome Measure Information:
Title
Number of participants with Grade 3 and Grade 4 possibly-related adverse events (PRAEs)
Description
To assess the safety and tolerability profile of durvalumab as defined by Grade 3 and Grade 4 PRAEs
Time Frame
From screening (day -28) to 6 months from the initiation of durvalumab treatment
Secondary Outcome Measure Information:
Title
Median Progression-free survival (PFS)
Description
To assess the efficacy of durvalumab treatment . PFS is defined as the time from the first date of treatment until the date of objective disease progression or death regardless of whether the patient withdraws from investigational product (IP) or receives another anticancer therapy prior to progression
Time Frame
From the first date of treatment until the date of objective disease progression or death (up to maximum 12 months)
Title
PFS at 6 months (PFS6)
Description
To assess the efficacy of durvalumab treatment . PFS is defined as the time from the first date of treatment until the date of objective disease progression or death regardless of whether the patient withdraws from IP or receives another anticancer therapy prior to progression
Time Frame
From the first date of treatment until the date of objective disease progression or death (up to maximum 6 months)
Title
PFS at 12 months (PFS12)
Description
To assess the efficacy of durvalumab treatment. PFS is defined as the time from the first date of treatment until the date of objective disease progression or death regardless of whether the patient withdraws from IP or receives another anticancer therapy prior to progression
Time Frame
From the first date of treatment until the date of objective disease progression or death (up to maximum 12 months)
Title
Median overall survival (OS)
Description
To assess the efficacy of durvalumab treatment. OS is defined as the time from the first date of treatment until death due to any cause
Time Frame
From the first date of treatment until death due to any cause (up to maximum 12 months)
Title
OS at 12 months (OS12)
Description
To assess the efficacy of durvalumab treatment. OS is defined as the time from the first date of treatment until death due to any cause
Time Frame
From the first date of treatment until death due to any cause (up to maximum 12 months)
Title
Objective response rate (ORR)
Description
To assess the efficacy of durvalumab treatment in terms of ORR based on Investigator assessments per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Time Frame
From 8 weeks ±1 week after investigational product (IP) treatment initiation and continue every 8 weeks (q8w) ±1 week through 48 weeks and every 12 weeks (q12w) ±1 week until disease progression (up to maximum of 12 months)
Title
Duration of response (DoR)
Description
To assess the efficacy of durvalumab treatment in terms of DoR. DoR is defined as the time from the date of first documented response per RECIST1.1 until the first date of documented progression per RECIST1.1 or death in the absence of disease progression
Time Frame
From 8 weeks ±1 week after IP treatment initiation and continue q8w ±1 week through 48 weeks and q12w ±1 week until disease progression (up to maximum of 12 months)
Title
Number of participants with lung cancer mortality
Description
To assess the efficacy of durvalumab treatment in terms of lung cancer mortality
Time Frame
From date of treatment start until death due to lung cancer (up to maximum of 12 months)
Title
Number of participants with adverse events, serious adverse events, adverse event of special interests, and immune-mediated adverse event
Description
To assess the safety and tolerability profile of durvalumab treatment
Time Frame
From screening (Day -28) till final visit (up to a maximum of 12 months)
Title
Number of participants with abnormal physical examinations
Description
To assess the safety and tolerability profile of durvalumab treatment
Time Frame
At screening
Title
Number of participants with abnormal blood pressure
Description
To assess the safety and tolerability profile of durvalumab treatment
Time Frame
From screening (Day -28) till final visit (up to a maximum of 12 months
Title
Number of participants with abnormal pulse
Description
To assess the safety and tolerability profile of durvalumab treatment
Time Frame
From screening (Day -28) till final visit (up to a maximum of 12 months)
Title
Number of participants with abnormal electrocardiograms
Description
To assess the safety and tolerability profile of durvalumab treatment
Time Frame
From screening (Day -28) till final visit (up to a maximum of 12 months)
Title
Number of participants with abnormal clinical chemistry
Description
To assess the safety and tolerability profile of durvalumab treatment
Time Frame
From screening (Day -28) till final visit (up to a maximum of 12 months)
Title
Number of participants with abnormal hematology
Description
To assess the safety and tolerability profile of durvalumab treatment
Time Frame
From screening (Day -28) till final visit (up to a maximum of 12 months
Title
Number of participants with abnormal urinalysis
Description
To assess the safety and tolerability profile of durvalumab treatment
Time Frame
From screening (Day -28) till final visit (up to a maximum of 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
130 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Capable of giving signed informed consent. Age ≥ 18 years at study entry. Histologically or cytologically documented NSCLC with locally-advanced, unresectable Stage III disease. Deemed ineligible for chemotherapy per Investigator assessment. Receipt of radiation therapy that was completed within 42 days prior to first study drug administration. Must have received a total dose of radiation of 40 to 66 Gy (standard or hypofractionated BED). Must not have progressed following radiation therapy, as per Investigator assessed RECIST 1.1 criteria: a) Patients with measurable disease and/or nonmeasurable and/or no evidence of disease assessed at baseline by computed tomography /magnetic resonance imaging will be eligible for this study. b) Prior irradiated lesions may be considered measurable and selected as target lesions (TLs) providing they fulfill the other criteria for measurability. World Health Organization/ECOG performance status of ≤2. No prior exposure to immune-mediated therapy including, but not limited to, anti-CTLA-4, anti-PD-1, anti-PD-L1, and antiprogrammed cell death ligand 2 (anti-PD-L2) antibodies, excluding therapeutic anticancer vaccines. Patients must have adequate organ and marrow function as defined below: Hemoglobin ≥ 9.0 g/dL Absolute neutrophil count ≥ 1.0 × 109 /L Platelet count ≥ 75 × 109/L Serum bilirubin ≤ 1.5 × the upper limit of normal (ULN). This will not apply to patients with confirmed Gilbert's syndrome. Alanine aminotransferase and aspartate aminotransferase ≤ 2.5 × ULN Measured creatinine clearance > 30 mL/min or calculated CL > 30 mL/min as determined by Cockcroft-Gault Life expectancy of greater than 12 weeks. Body weight greater than 30 kg at study entry and at first study drug administration Exclusion Criteria: Patients with locally-advanced NSCLC whose disease has progressed following radiation therapy. Mixed small cell lung cancer and NSCLC histology. History of allogeneic organ transplantation. Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative, systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome). Uncontrolled intercurrent illness (e.g., ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris) History of another primary malignancy except for (a) malignancy treated with curative intent and with no known active disease ≥ 5 years before the first study drug administration, (b) adequately treated nonmelanoma skin cancer or lentigo maligna without evidence of disease, and c) treated carcinoma in situ without evidence of disease. History of leptomeningeal carcinomatosis History of active primary immunodeficiency Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus Any unresolved toxicity NCI CTCAE Grade ≥ 2 from previous anticancer therapy with the exception of alopecia, vitiligo, lymphopenia, and the laboratory values defined in the inclusion criteria Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients. Receipt of live attenuated vaccine within 30 days prior to the first dose of durvalumab Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of durvalumab. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. Participation in another clinical study with an IP administered in the last 4 weeks. Concurrent enrollment in another clinical study, unless it is an observational (noninterventional) clinical study or during the follow-up period of an interventional study Prior randomization or treatment in a previous durvalumab clinical study regardless of treatment arm assignment Patients who refuse chemotherapy by their own decision. Involvement in the planning and/or conduct of the study Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control. Judgment by the Investigator that the patient should not participate in the study Genetics research study (optional): Exclusion criteria for participation in the optional genetics research component of the study include: a) Previous allogeneic bone marrow transplant b)Nonleukocyte-depleted whole blood transfusion within 120 days of genetic sample collection.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dr Andrea Riccardo Filippi
Organizational Affiliation
Fondazione IRCCS Policlinico San Matteo
Official's Role
Principal Investigator
Facility Information:
Facility Name
Research Site
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85704
Country
United States
Facility Name
Research Site
City
Tampa
State/Province
Florida
ZIP/Postal Code
33612
Country
United States
Facility Name
Research Site
City
Royal Oak
State/Province
Michigan
ZIP/Postal Code
48073
Country
United States
Facility Name
Research Site
City
Limoges
ZIP/Postal Code
87000
Country
France
Facility Name
Research Site
City
Marseille
ZIP/Postal Code
13009
Country
France
Facility Name
Research Site
City
Montpellier
ZIP/Postal Code
34070
Country
France
Facility Name
Research Site
City
Nimes
ZIP/Postal Code
30029
Country
France
Facility Name
Research Site
City
Rouen
ZIP/Postal Code
76031
Country
France
Facility Name
Research Site
City
Brescia
ZIP/Postal Code
25100
Country
Italy
Facility Name
Research Site
City
Firenze
ZIP/Postal Code
50134
Country
Italy
Facility Name
Research Site
City
Genova
ZIP/Postal Code
16132
Country
Italy
Facility Name
Research Site
City
Meldola
ZIP/Postal Code
47014
Country
Italy
Facility Name
Research Site
City
Messina
ZIP/Postal Code
98158
Country
Italy
Facility Name
Research Site
City
Modena
ZIP/Postal Code
41124
Country
Italy
Facility Name
Research Site
City
Monza
ZIP/Postal Code
20900
Country
Italy
Facility Name
Research Site
City
Negrar
ZIP/Postal Code
37024
Country
Italy
Facility Name
Research Site
City
Pavia
ZIP/Postal Code
27100
Country
Italy
Facility Name
Research Site
City
Pisa
ZIP/Postal Code
56124
Country
Italy
Facility Name
Research Site
City
Ravenna
ZIP/Postal Code
48121
Country
Italy
Facility Name
Research Site
City
Roma
ZIP/Postal Code
00128
Country
Italy
Facility Name
Research Site
City
Białystok
ZIP/Postal Code
15-044
Country
Poland
Facility Name
Research Site
City
Gdańsk
ZIP/Postal Code
80-214
Country
Poland
Facility Name
Research Site
City
Olsztyn
ZIP/Postal Code
10-228
Country
Poland
Facility Name
Research Site
City
Szczecin
ZIP/Postal Code
71-730
Country
Poland
Facility Name
Research Site
City
Warszawa
ZIP/Postal Code
02-781
Country
Poland
Facility Name
Research Site
City
St. Petersburg
ZIP/Postal Code
197002
Country
Russian Federation
Facility Name
Research Site
City
St. Petersburg
ZIP/Postal Code
197758
Country
Russian Federation
Facility Name
Research Site
City
Ufa
ZIP/Postal Code
450054
Country
Russian Federation
Facility Name
Research Site
City
A Coruña
ZIP/Postal Code
15006
Country
Spain
Facility Name
Research Site
City
Barcelona
ZIP/Postal Code
8035
Country
Spain
Facility Name
Research Site
City
Castello de la Plana
ZIP/Postal Code
12002
Country
Spain
Facility Name
Research Site
City
Madrid
ZIP/Postal Code
28050
Country
Spain
Facility Name
Research Site
City
Oviedo
ZIP/Postal Code
33011
Country
Spain
Facility Name
Research Site
City
Pamplona
ZIP/Postal Code
31008
Country
Spain
Facility Name
Research Site
City
Sabadell(Barcelona)
ZIP/Postal Code
08208
Country
Spain

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD Sharing Time Frame
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD Sharing Access Criteria
When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD Sharing URL
https://astrazenecagroup-dt.pharmacm.com/DT/Home
Citations:
PubMed Identifier
34775804
Citation
Filippi AR, Dziadziuszko R, Garcia Campelo MR, Paoli JB, Sawyer W, Diaz Perez IE. DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy. Future Oncol. 2021 Dec;17(34):4657-4663. doi: 10.2217/fon-2021-0952. Epub 2021 Nov 15.
Results Reference
derived

Learn more about this trial

Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy

We'll reach out to this number within 24 hrs